Mandate

Vinge advises Manor Investment S.A. on investment in Rabbalshede Kraft AB (publ)

June 20, 2013

Vinge is advising Manor Investment S.A. in connection with its investment in Rabbalshede Kraft AB (publ). The investment is made through inter alia acquisition of newly issued shares of class B in a private placement, acquisition of 347,500 shares of class A from certain of the current main shareholders, and through acquisition of newly issued shares of class B in a rights issue. Manor is a private industrial company within the renewable energy sector providing long-term development capital to entrepreneurs and industrial projects in Europe aiming for the better use of energy and natural resources. Rabbalshede develops and operates wind power farms in Sweden, with a current portfolio of 26 wind turbines proprietarily managed, 14 turbines under construction and about 350 turbines in the procurement, application or planning phase. Closing of the transactions is subject to certain conditions precedent. Manor is advised by Treïs (www.treispartners.com).

The Vinge team advising Manor includes partner Michael Wigge and associates Peter Sundgren and Louise Markgren (M&A), partner Thomas Sjöberg and associate Johan Cederblad (Real Estate & Environmental), and associate Albert Wållgren (Banking & Finance).

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025